Oncimmune

About:

Oncimmune engaged in developing and commercializing its EarlyCDT platform technology.

Website: http://oncimmune.com/

Twitter/X: OncimmuneECDT

Top Investors: Balderton Capital, SBRI Healthcare, Claret Capital Partners

Description:

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.